Common drug review refuses to recommend public access of unique once-yearly osteoporosis treatment
Aclasta® is the first and only treatment for women with postmenopausal osteoporosis (PMO) that is administered once-yearly. Aclasta* is given as a 15-minute intravenous (IV) infusion that can be done at a doctor’s office or at home.
Quebec becomes the first province to recognize the importance of an innovative treatment for Alzheimer’s disease
Exelon® Patch, the first and only transdermal therapy for the symptomatic treatment of mild to moderate Alzheimer's disease is now reimbursed in Quebec.
Canadians diagnosed with the leading cause of age-related vision loss, neovascular (wet) age-related macular degeneration (AMD), are one step closer today to real hope for vision improvement. The Common Drug Review (CDR), Canada’s national drug review process, has recommended today that provincial drug plans list the innovative treatment Lucentis* (ranibizumab).
New Treatment for Heart Failure Approved by Health Canada
Health Canada has approved Diovan* (valsartan) for the treatment of chronic heart failure (HF) in patients who are intolerant of angiotensin-converting-enzyme (ACE) inhibitors.
You are now leaving the Novartis Pharmaceuticals Canada Inc. site.
This link leads to resources located on servers maintained by third parties over whom Novartis Pharmaceuticals Canada Inc. has no control. As such, Novartis Pharmaceuticals Canada Inc. makes no representation as to the accuracy or any other aspect of the information contained on such servers.
